Brazil's new rules on antibiotic prescriptions are good news for multinationals
This article was originally published in SRA
A new resolution that has just come into force in Brazil means that patients will only be able to buy drugs containing antimicrobials with a controlled prescription1. Although the measure came largely in response to concerns over increasing resistance to antibiotics, it is also a positive move for multinationals because it means that if a doctor prescribes a brand, the pharmacist is more likely to actually dispense it.
You may also be interested in...
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.
EFPIA, the European Federation of Pharmaceutical Industries and Associations, has put forward what it thinks the European regulatory network strategy to 2025 should prioritize.